Company Description
Labcorp Holdings Inc. provides laboratory services.
It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs).
In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing.
It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers.
The company was founded in 1995 is headquartered in Burlington, North Carolina.
| Country | United States |
| Founded | 1971 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 67,000 |
| CEO | Adam Schechter |
Contact Details
Address: 358 South Main Street Burlington, North Carolina 27215 United States | |
| Phone | 336 229 1127 |
| Website | labcorp.com |
Stock Details
| Ticker Symbol | LH |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000920148 |
| CUSIP Number | 50540R409 |
| ISIN Number | US50540R4092 |
| Employer ID | 99-2588107 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Adam H. Schechter | President, Chief Executive Officer and Chairman |
| Glenn A. Eisenberg | Chief Financial Officer and Executive Vice President |
| Mark S. Schroeder | Executive Vice President, President of Diagnostics Laboratories and Chief Operating Officer |
| Dr. Brian J. Caveney J.D., M.D., M.P.H. | EVice President, President of Early Development Research Laboratories and Chief Medical and Scientific Officer |
| Anita Z. Graham | Executive Vice President and Chief Human Resources Officer |
| Peter J. Wilkinson | Senior Vice President and Chief Accounting Officer |
| Lance V. Berberian | Executive Vice President and Chief Information and Technology Officer |
| Christin O'Donnell | Vice President of Investor Relations |
| Sandra D. van der Vaart J.D. | Executive Vice President, Chief Legal Officer and Corporate Secretary |
| Amy B. Summy | Executive Vice President and Chief Marketing Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2024 | 10-Q | Quarterly Report |
| Oct 24, 2024 | 144 | Filing |
| Oct 24, 2024 | 8-K | Current Report |
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 10, 2024 | 8-K | Current Report |
| Sep 24, 2024 | 8-K | Current Report |
| Sep 23, 2024 | 8-K | Current Report |
| Sep 18, 2024 | 8-K | Current Report |
| Sep 18, 2024 | 424B5 | Filing |
| Sep 16, 2024 | FWP | Free Writing Prospectus |